vs
ASTROTECH Corp（ASTC）与HARVARD BIOSCIENCE INC（HBIO）财务数据对比。点击上方公司名可切换其他公司
HARVARD BIOSCIENCE INC的季度营收约是ASTROTECH Corp的160.4倍（$23.7M vs $148.0K）。HARVARD BIOSCIENCE INC净利率更高（-12.0% vs -2653.4%，领先2641.4%）。HARVARD BIOSCIENCE INC同比增速更快（-3.3% vs -43.3%）。HARVARD BIOSCIENCE INC自由现金流更多（$-545.0K vs $-4.0M）。过去两年ASTROTECH Corp的营收复合增速更高（72.0% vs -1.6%）
航天科技公司（原名Spacehab Inc.）是一家总部位于美国得克萨斯州奥斯汀的科技孵化企业。该公司整合内部、研究机构、政府实验室及高校的技术资源，投资、孵化并退出初创企业，旗下子公司还为美国航空航天局、美国国防部、各国航天机构及全球商业客户提供商业化产品与服务。
哈佛生物科学是一家全球生命科学设备开发商、制造商与销售商，其产品主要用于支撑科研开发与药物研发工作，目前该公司在纳斯达克上市，股票交易代码为HBIO。
ASTC vs HBIO — 直观对比
营收规模更大
HBIO
是对方的160.4倍
$148.0K
营收增速更快
HBIO
高出40.0%
-43.3%
净利率更高
HBIO
高出2641.4%
-2653.4%
自由现金流更多
HBIO
多$3.4M
$-4.0M
两年增速更快
ASTC
近两年复合增速
-1.6%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $148.0K | $23.7M |
| 净利润 | $-3.9M | $-2.8M |
| 毛利率 | 5.4% | 59.7% |
| 营业利润率 | -2635.8% | 7.2% |
| 净利率 | -2653.4% | -12.0% |
| 营收同比 | -43.3% | -3.3% |
| 净利润同比 | 2.0% | -15916.7% |
| 每股收益（稀释后） | — | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTCHBIO
| Q4 25 | $148.0K | $23.7M | ||
| Q3 25 | $297.0K | $20.6M | ||
| Q2 25 | $220.0K | $20.4M | ||
| Q1 25 | $534.0K | $21.8M | ||
| Q4 24 | $261.0K | $24.6M | ||
| Q3 24 | $34.0K | $22.0M | ||
| Q2 24 | $74.0K | $23.1M | ||
| Q1 24 | $50.0K | $24.5M |
净利润ASTCHBIO
| Q4 25 | $-3.9M | $-2.8M | ||
| Q3 25 | $-3.5M | $-1.2M | ||
| Q2 25 | $-2.9M | $-2.3M | ||
| Q1 25 | $-3.6M | $-50.3M | ||
| Q4 24 | $-4.0M | $18.0K | ||
| Q3 24 | $-3.3M | $-4.8M | ||
| Q2 24 | $-3.0M | $-2.9M | ||
| Q1 24 | $-3.2M | $-4.7M |
毛利率ASTCHBIO
| Q4 25 | 5.4% | 59.7% | ||
| Q3 25 | 63.3% | 58.4% | ||
| Q2 25 | 33.6% | 56.4% | ||
| Q1 25 | 44.4% | 56.0% | ||
| Q4 24 | 59.4% | 57.1% | ||
| Q3 24 | 26.5% | 58.1% | ||
| Q2 24 | 37.8% | 57.2% | ||
| Q1 24 | 16.0% | 60.3% |
营业利润率ASTCHBIO
| Q4 25 | -2635.8% | 7.2% | ||
| Q3 25 | -1190.6% | 1.0% | ||
| Q2 25 | -1326.4% | -4.0% | ||
| Q1 25 | -724.2% | -228.1% | ||
| Q4 24 | -1655.6% | 0.0% | ||
| Q3 24 | -10670.6% | -8.5% | ||
| Q2 24 | -4518.9% | -9.0% | ||
| Q1 24 | -7066.0% | -9.3% |
净利率ASTCHBIO
| Q4 25 | -2653.4% | -12.0% | ||
| Q3 25 | -1166.7% | -6.0% | ||
| Q2 25 | -1331.8% | -11.2% | ||
| Q1 25 | -680.3% | -231.2% | ||
| Q4 24 | -1536.0% | 0.1% | ||
| Q3 24 | -9641.2% | -21.9% | ||
| Q2 24 | -3998.6% | -12.7% | ||
| Q1 24 | -6308.0% | -19.1% |
每股收益（稀释后）ASTCHBIO
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $-1.14 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | — | $-0.11 | ||
| Q2 24 | — | $-0.07 | ||
| Q1 24 | — | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.0M | $8.6M |
| 总债务越低越好 | — | $35.9M |
| 股东权益账面价值 | $15.5M | $13.7M |
| 总资产 | $19.7M | $80.1M |
| 负债/权益比越低杠杆越低 | — | 2.61× |
8季度趋势，按日历期对齐
现金及短期投资ASTCHBIO
| Q4 25 | $7.0M | $8.6M | ||
| Q3 25 | $11.3M | $6.8M | ||
| Q2 25 | $15.1M | $7.4M | ||
| Q1 25 | $18.1M | $5.5M | ||
| Q4 24 | $21.5M | $4.1M | ||
| Q3 24 | $21.8M | $4.6M | ||
| Q2 24 | $42.9M | $4.0M | ||
| Q1 24 | $52.4M | $4.3M |
总债务ASTCHBIO
| Q4 25 | — | $35.9M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $34.9M | ||
| Q1 25 | — | $36.4M | ||
| Q4 24 | — | $37.0M | ||
| Q3 24 | — | $34.9M | ||
| Q2 24 | — | $35.7M | ||
| Q1 24 | — | $35.6M |
股东权益ASTCHBIO
| Q4 25 | $15.5M | $13.7M | ||
| Q3 25 | $19.1M | $14.1M | ||
| Q2 25 | $22.1M | $15.7M | ||
| Q1 25 | $24.8M | $14.8M | ||
| Q4 24 | $28.1M | $63.3M | ||
| Q3 24 | $32.1M | $65.3M | ||
| Q2 24 | $34.8M | $67.2M | ||
| Q1 24 | $37.6M | $68.8M |
总资产ASTCHBIO
| Q4 25 | $19.7M | $80.1M | ||
| Q3 25 | $23.2M | $78.0M | ||
| Q2 25 | $27.0M | $80.1M | ||
| Q1 25 | $27.5M | $79.8M | ||
| Q4 24 | $31.0M | $126.6M | ||
| Q3 24 | $34.4M | $131.2M | ||
| Q2 24 | $37.6M | $128.9M | ||
| Q1 24 | $40.2M | $133.2M |
负债/权益比ASTCHBIO
| Q4 25 | — | 2.61× | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 2.22× | ||
| Q1 25 | — | 2.45× | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.52× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.5M | $-96.0K |
| 自由现金流经营现金流 - 资本支出 | $-4.0M | $-545.0K |
| 自由现金流率自由现金流/营收 | -2671.6% | -2.3% |
| 资本支出强度资本支出/营收 | 277.7% | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-14.9M | $5.5M |
8季度趋势，按日历期对齐
经营现金流ASTCHBIO
| Q4 25 | $-3.5M | $-96.0K | ||
| Q3 25 | $-3.9M | $1.1M | ||
| Q2 25 | $-2.4M | $2.8M | ||
| Q1 25 | $-3.9M | $3.0M | ||
| Q4 24 | $-3.0M | $1.7M | ||
| Q3 24 | $-3.7M | $-842.0K | ||
| Q2 24 | $-2.5M | $-846.0K | ||
| Q1 24 | $-2.3M | $1.4M |
自由现金流ASTCHBIO
| Q4 25 | $-4.0M | $-545.0K | ||
| Q3 25 | $-4.4M | $877.0K | ||
| Q2 25 | $-2.7M | $2.7M | ||
| Q1 25 | $-3.9M | $2.5M | ||
| Q4 24 | $-3.4M | $1.4M | ||
| Q3 24 | $-3.9M | $-1.7M | ||
| Q2 24 | $-2.8M | $-1.7M | ||
| Q1 24 | $-2.5M | $758.0K |
自由现金流率ASTCHBIO
| Q4 25 | -2671.6% | -2.3% | ||
| Q3 25 | -1476.1% | 4.3% | ||
| Q2 25 | -1231.4% | 13.0% | ||
| Q1 25 | -728.1% | 11.4% | ||
| Q4 24 | -1288.5% | 5.8% | ||
| Q3 24 | -11408.8% | -7.8% | ||
| Q2 24 | -3728.4% | -7.2% | ||
| Q1 24 | -5036.0% | 3.1% |
资本支出强度ASTCHBIO
| Q4 25 | 277.7% | 1.9% | ||
| Q3 25 | 150.8% | 1.0% | ||
| Q2 25 | 158.2% | 0.4% | ||
| Q1 25 | 5.1% | 2.4% | ||
| Q4 24 | 122.2% | 1.2% | ||
| Q3 24 | 567.6% | 4.0% | ||
| Q2 24 | 305.4% | 3.5% | ||
| Q1 24 | 352.0% | 2.6% |
现金转化率ASTCHBIO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 95.83× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTC
暂无分部数据
HBIO
| Instruments Equipment Software And Accessories | $21.6M | 91% |
| Service Maintenance And Warranty Contracts | $2.1M | 9% |
